LG Life Sciences has developed and commercialized an array of pharmaceuticals over the years. From Interferon in 1989 (Intermax-gamma) and 1992 (Intermax-alpha), to Hepatitis B vaccine in 1992
(EUVAX B™), and recently next-generation quinolone antibiotic (FACTIVE®) was approved by the FDA in the United States.
To this end, LGLS is expanding its strategic alliances and fostering its capabilities to identify candidate drugs for development. Indeed, the company’s development of new medicines is accelerating and marketing competencies are being focused on advanced markets.
Industry
Pharmaceutical